Lupin receives approval from U.S. FDA for Tolvaptan Tablets

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Tolvaptan Tablets are bioequivalent to Jynarque® Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, Ltd. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility in India and will be launched soon.

Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

"We are very pleased to have obtained approval for generic Tolvaptan from the U.S. FDA. This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally," said Vinita Gupta, CEO, Lupin.

Tolvaptan Tablets (RLD Jynarque®) had an estimated annual sale of USD 1,467 million in the U.S. (fiscal year ended December 31, 2024).

Shares of Lupin Limited was last trading in BSE at Rs. 2088.85 as compared to the previous close of Rs. 2046.90. The total number of shares traded during the day was 160258 in over 10226 trades.

The stock hit an intraday high of Rs. 2103.35 and intraday low of 2035.15. The net turnover during the day was Rs. 334283435.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Approval USFDA TolvaptanTablets